OncoMatch/Clinical Trials/NCT04375813
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
Is NCT04375813 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies eRapa for non-muscle invasive bladder cancer.
Treatment: eRapa — eRapa (encapsulated rapamycin) will be investigated for secondary prevention in patients with diagnosed non-muscle invasive bladder cancer (NMIBC) through a phase II double-blind randomized controlled trial of long-term (one year) prevention with eRapa versus placebo. The primary hypothesis is that eRapa decreases the risk of cancer relapse for patients with NMIBC. Secondary hypotheses are that eRapa can improve certain immune parameters and improve cognition and physical function without adversely affecting patient-reported outcomes and quality of life.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Disease stage
Required: Stage TIS
Excluded: Stage ≥T2
non-muscle invasive (Ta, Tis, or T1) bladder cancer; Have muscle-invasive or higher (≥T2) bladder cancer [excluded]
Prior therapy
Cannot have received: intravesical bcg
Cannot have received: rapamycin
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UT Southwestern Medical Center · Dallas, Texas
- UT Health San Antonio · San Antonio, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify